Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) EBITDA Margin (2024 - 2025)

Historic EBITDA Margin for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Q3 2025 value amounting to 211.11%.

  • Monte Rosa Therapeutics' EBITDA Margin rose 440000.0% to 211.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.03%, marking a year-over-year increase of 8140700.0%. This contributed to the annual value of 96.97% for FY2024, which is N/A changed from last year.
  • Per Monte Rosa Therapeutics' latest filing, its EBITDA Margin stood at 211.11% for Q3 2025, which was up 440000.0% from 53.2% recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year EBITDA Margin high stood at 55.24% for Q1 2025, and its period low was 3001.6% during Q1 2024.